Legend Capital co-leads $293m round in Chinese Diagnostics Medical Corp

Legend Capital co-leads $293m round in Chinese Diagnostics Medical Corp

An automated machine works on purification of potential hepatitis C virus drug candidate at the Gilead Sciences Inc. lab in Foster City, California, U.S., on Wednesday, Feb. 8, 2012. Photographer: David Paul Morris/Bloomberg

Legend Capital, the venture and growth capital arm of China’s Legend Holdings Ltd, has co-led an RMB2 billion ($293 million) investment in Chinese Diagnostics Medical Corporation by joining China Renaissance’s healthcare fund, China Money Network reported.

Other investors including Matrix Partners, Ping An Ventures, High Light Capital, Zhongjin Kangrui Healthcare Industrial Fund, and Shanghai Free Trade Zone Equity Fund (FTZ Fund) also participated in the round.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter